ROYAL BANK OF CANADA - SYROS PHARMACEUTICALS INC ownership

SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 78 filers reported holding SYROS PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2022$0
-100.0%
533
-84.9%
0.00%
Q1 2022$4,000
-90.0%
3,537
-71.7%
0.00%
Q4 2021$40,000
+81.8%
12,499
+156.0%
0.00%
Q3 2021$22,000
+4.8%
4,882
+23.9%
0.00%
Q2 2021$21,000
+40.0%
3,941
+101.8%
0.00%
Q1 2021$15,000
+7.1%
1,953
+55.4%
0.00%
Q4 2020$14,000
-86.0%
1,257
-88.8%
0.00%
Q3 2020$100,000
+53.8%
11,262
+85.5%
0.00%
Q2 2020$65,000
+6400.0%
6,070
+3272.2%
0.00%
Q1 2020$1,000
-90.9%
180
-88.2%
0.00%
Q4 2019$11,0001,521
+5144.8%
0.00%
Q4 2018$0
-100.0%
29
-94.8%
0.00%
Q3 2018$6,000
+200.0%
563
+270.4%
0.00%
Q2 2018$2,000152
+406.7%
0.00%
Q4 2017$0
-100.0%
30
-97.2%
0.00%
Q3 2017$16,0001,068
+4754.5%
0.00%
Q2 2017$0
-100.0%
22
-96.3%
0.00%
Q1 2017$10,000
+233.3%
599
+152.7%
0.00%
Q4 2016$3,000
+200.0%
237
+137.0%
0.00%
Q3 2016$1,0001000.00%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q3 2018
NameSharesValueWeighting ↓
ARCH Venture Management, LLC 200,000$1,768,0008.83%
Samsara BioCapital, LLC 1,407,949$11,608,0003.24%
Flagship Pioneering Inc. 2,938,494$25,976,0000.72%
ARK Investment Management 11,212,506$99,119,0000.59%
Portolan Capital Management 450,861$3,986,0000.45%
Capital Impact Advisors, LLC 168,600$1,490,0000.44%
Nikko Asset Management Americas, Inc. 4,182,346$36,261,0000.32%
Sio Capital Management, LLC 166,780$1,474,0000.29%
Virtus ETF Advisers LLC 34,835$308,0000.16%
Artal Group S.A. 465,500$4,115,0000.10%
View complete list of SYROS PHARMACEUTICALS INC shareholders